GENE ONLINE|News &
Opinion
Blog

2021-03-23| In-DepthM&ASpecial

Overview of the Gene Therapy Revolution: Hopeful Beginnings, Tribulations, and Resurgence

by Rajaneesh K. Gopinath
Share To
Gene therapy is a hot commodity in the biopharma business, attracting profitable investments and expensive M&A transactions in recent years.

Moreover, the frequent reports of research breakthroughs and clinical trial gains are an indication of the steady progress of the field. In 2019, the gene therapy market was valued at $3.61 billion. It is predicted to grow further at a CAGR of 33.6% and reach $35.67 billion by 2027, according to a forecast released by Fortune Business Insights™.

GO Prime with only $1.49 now

LATEST
Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
2024-07-12
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
2024-07-12
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
2024-07-12
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
2024-07-11
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
2024-07-11
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
2024-07-11
EVENT
Scroll to Top